{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:16:54Z","timestamp":1792023414219,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01340-1","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T14:33:48Z","timestamp":1772289228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors"],"prefix":"10.1038","volume":"10","author":[{"given":"Gerald","family":"Falchook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Braganca Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Van Veenhuyzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sommerhalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garrido-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"1340_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission Possible?. Nat. Rev. Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1340_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9859","volume":"6","author":"S Bunda","year":"2015","unstructured":"Bunda, S. et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat. Commun. 6, 8859 (2015).","journal-title":"Nat. Commun."},{"key":"1340_CR3","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279\u20133290 (2007).","journal-title":"Oncogene"},{"key":"1340_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc1360","volume":"4","author":"A Gschwind","year":"2004","unstructured":"Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4, 361\u2013370 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"1340_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0969-2126(98)00027-6","volume":"6","author":"D Barford","year":"1998","unstructured":"Barford, D. & Neel, B. G. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 6, 249\u2013254 (1998).","journal-title":"Structure"},{"key":"1340_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd.2018.201","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard, A. Phosphatases start shedding their stigma of undruggability. Nat. Rev. Drug Discov. 17, 847\u2013849 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1340_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","volume":"62","author":"DL Kerr","year":"2021","unstructured":"Kerr, D. L., Haderk, F. & Bivona, T. G. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Curr. Opin. Chem. Biol. 62, 1\u201312 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1340_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","volume":"11","author":"Z Song","year":"2021","unstructured":"Song, Z. et al. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharm. Sin. B 11, 13\u201329 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"1340_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2016.07.010","volume":"30","author":"H Ran","year":"2016","unstructured":"Ran, H., Tsutsumi, R., Araki, T. & Neel, B. G. Sticking It to Cancer with Molecular Glue for SHP2. Cancer Cell 30, 194\u2013196 (2016).","journal-title":"Cancer Cell"},{"key":"1340_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"Y-NP Chen","year":"2016","unstructured":"Chen, Y.-N. P. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535, 148\u2013152 (2016).","journal-title":"Nature"},{"key":"1340_CR11","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1200\/JCO.2021.39.15_suppl.3005","volume":"39","author":"I Brana","year":"2021","unstructured":"Brana, I. et al. Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors. J. Clin. Oncol. 39, 3005 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1340_CR12","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jtho.2019.12.041","volume":"15","author":"SI Ou","year":"2020","unstructured":"Ou, S. I. et al. A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial. J. Thorac. Oncol. 15, S15\u2013S16 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"1340_CR13","doi-asserted-by":"publisher","first-page":"P207","DOI":"10.1158\/1535-7163.TARG-21-P207","volume":"20","author":"JP Stice","year":"2021","unstructured":"Stice, J. P. et al. Abstract P207: BBP-398, a potent, small molecule inhibitor of SHP2, enhances the response of established NSCLC xenografts to KRASG12C and mutEGFR inhibitors. Mol. Cancer Ther. 20, P207 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1340_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","volume":"27","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clin. Cancer Res. 27, 342\u2013354 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1340_CR15","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1200\/JCO.2023.41.16_suppl.3020","volume":"41","author":"AE Drilon","year":"2023","unstructured":"Drilon, A. E. et al. A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors. J. Clin. Oncol. 41, 3020 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1340_CR16","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S0959-8049(22)00890-5","volume":"174","author":"M McKean","year":"2022","unstructured":"McKean, M. et al. Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. Eur. J. Cancer 174, S34 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1340_CR17","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3390\/cancers11091262","volume":"11","author":"KC Schreck","year":"2019","unstructured":"Schreck, K. C., Grossman, S. A. & Pratilas, C. A. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers 11, 1262 (2019).","journal-title":"Cancers"},{"key":"1340_CR18","doi-asserted-by":"crossref","unstructured":"\u00d6zg\u00fc, E. et al. Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors. BJC Rep. 2, (2024).","DOI":"10.1038\/s44276-024-00086-2"},{"key":"1340_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-80999-x","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Sci. Rep. 11, 1399 (2021).","journal-title":"Sci. Rep."},{"key":"1340_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","volume":"9","author":"M Zhao","year":"2019","unstructured":"Zhao, M. et al. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade. Acta Pharm. Sin. B 9, 304\u2013315 (2019).","journal-title":"Acta Pharm. Sin. B"},{"key":"1340_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.36401\/JIPO-24-23","volume":"7","author":"CDH Lopes","year":"2024","unstructured":"Lopes, C. D. H., Braganca Xavier, C., Torrado, C., Veneziani, A. C. & Megid, T. B. C. A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives. J. Immunother. Precis. Oncol. 7, 283\u2013299 (2024).","journal-title":"J. Immunother. Precis. Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01340-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01340-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01340-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:13:12Z","timestamp":1775733192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01340-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01340-1","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.F. has received royalties from Wolters Kluwer; been an advisor for AbbVie, Jubilant, BostonGene, Teon, Merck, Sanofi, BridgeBio, and Beijing Avistone (2024); received a speaker honorarium from Clinical Care Options; received travel funds from Sarah Cannon Research Institute, Amgen, Synthorx\/Sanofi, GSK, and Cyteir; and received research funding from Abbisko, ABL Bio, Abbvie, ADC Therapeutics, Accutar, Agenus, Aileron, Alterome, Amgen, Arcus, ARMO\/Eli Lilly, Artios, Astellas, AstraZeneca, Bayer, BeiGene, Beijing Avistone, Bioatla, Bioinvent, Biomea Fusion, Bicycle, Black Diamond, Boehringer Ingelheim, Boundless, Centessa, Conjupro, Cyteir, Cytomx, D3 Bio, Daiichi, Deciphera, Dynamicure, Eikon, Eli Lilly, Epizyme, Erasca, Exelixis, Freenome, Fujifilm, GSK, Harbour BioMed, Hutchison MediPharma, IGM Biosciences, IDEAYA, Ikena, Immuneering, Immunitas, ImmunoGen\/MacroGenics, Incyte, Jacobio, Jazz, Jounce, Jubilant, Kineta, Kumquat, Kura, Loxo\/Bayer, Medilink, Merck, Metabomed, Mirati, ModeX, Molecular Templates, Nammi, Navire\/BridgeBio, NGM Bio, NiKang, Novartis, Nuvalent, Nuvectis, Oncorus, Oncusp, OnKure, Phanes, Poseida, Prelude, PureTech, Pyramid, Pyxis, Quanta, RasCal, Regeneron, Relay, Rgenix, Ribon, Roche, Samumed, Sapience, Sarah Cannon Development Innovations, Seagen, Silicon\/Stingthera, Simcha, Sirnaomics, Synthorx\/Sanofi, Tachyon, Takeda, Tallac, Tango, Tarus, Tarveda, Teneobio, Tesaro, TORL, Turning Point, Xencor, and Zhuhai Yufan. D.V.V. has been employed by Navire Pharma. J.M. has been an advisor for Astra Zeneca, Janssen, Abbvie, Jazz, Sanofi, Bristol Myers Squibb, Takeda, and Daiichi Sankyo; been a consultant for Regeneron and Bristol Myers Squibb; been a Data Safety and Monitoring Committee member for Bioatla; and received research funding from NCI\/ARPA-H and Astra Zeneca. S.S. has been a consultant and\/or served on the speaker bureau for Eisai and BMS. A.R.K. has received grants and\/or personal fees from Pfizer, AstraZeneca, Bristol Myers Squibb, EMD Serono, Exelixis, Genentech, Gilead Sciences, Immunomedics, Novartis, Seattle Genetics\/Astellas, Amgen, Astellas Medivation, AVEO, Eisai, Genentech\/Roche, Janssen, Merck, Myovant Sciences, Sanofi, Bayer, Arvinas, Mirati Therapeutics, and POINT Biopharma and has stock and other ownership interests in ECOM Medical. L.W. has been employed by Navire Pharma. F.R. has received consulting fees from Eikon Therapeutics. E.L. has received consulting fees from Navire Pharma for performing the data analyses and summaries for the present study, which may be considered a potential conflict of interest with respect to the subject matter of this manuscript. A.I.S. has been a consultant or advisor for Incyte, Amgen, Novartis, Mirati Therapeutics, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Mersana, Gritstone bio, Daiichi Sankyo\/AstraZeneca, Regeneron, Eli Lilly, Black Diamond Therapeutics, Sanofi, ArriVent Biopharma, Synthekine, GSK, Crispr Therapeutics, and Revolution Medicines and has received research funding from LAM Therapeutics, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Incyte, AbbVie, Ignyta, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol-Myers Squibb, Loxo, Gritstone bio, Plexxikon, Amgen, Daiichi Sankyo, ADC Therapeutics, Janssen Oncology, Rubius, Synthekine, Mersana, Blueprint Medicines, Regeneron, Alkermes, Revolution Medicines, Medikine, Black Diamond Therapeutics, BluPrint Oncology, Nalo Therapeutics, Scorpion Therapeutics, ArriVent Biopharma, Prelude Therapeutics, and Eli Lilly. D.S. has been an employee and shareholder of Texas Oncology, a shareholder of NEXT Oncology, received honoraria from Syneos, received consulting fees from Guidepoint, received advisory board payments from Revolution Medicines and Nimbus Therapeutics, and received ongoing or past institutional research funding for studies from Abbvie, Acrivon Therapeutics, ADC Therapeutics, Aprea Therapeutics, Ascentage Pharma Group, Astellas, Avenzo Therapeutics, Biomea Fusion, Boehringer Ingelheim, BJ Bioscience, BioNTech, Bristol Myers Squibb, Compugen, Day One Biopharma, Dicerna\/Novo Nordisk, Dren Bio, Exelixis, Fate Therapeutics, Gilead Sciences, GSK, Haihe Pharmaceutical, Iconovir Bio, Ideaya Biosciences, Immuneering, Impact Therapeutics, Incendia, Kura Oncology, MediLink Therapeutics, Mirati Therapeutics, ModeX Therapeutics, Monopteros Therapeutics, Navire Pharma, Nimbus Therapeutics, NGM Biopharmaceuticals, OBI Pharma, OncoResponse, Pfizer, Revolution Medicines, Step Pharmaceuticals, Symphogen, Tachyon Therapeutics, Teon Therapeutics, Tyligand Bioscience, Vincerx Pharma, Vividion Therapeutics, ZielBio, and Zymeworks. I.G.-L. has been a consultant or advisor for SOTIO, AbbVie, Revolution Medicines, Eli Lilly, and Quanta Therapeutics and received research funding from EcoR1, Guidepoint, Novartis, Bayer, Bristol Myers Squibb, Pfizer, MedImmune, Eli Lilly, Incyte, GSK, Tolero Pharmaceuticals, BridgeBio Pharma, Jacobio, Repare Therapeutics, Sumitomo Dainippon Pharma Oncology, Revolution Medicines, Yingli Pharma, Quanta Therapeutics, 280 BIO, ABM Therapeutics, and Tango. D.S.H. has been a consultant or advisor for AbbVie, Acuta, Alpha Insights, Amgen, Axiom, BeiGene, Boxer Capital, COR2ed, EcoR1, Erasca, GLG, Guidepoint, ImmunoGen, Kestrel Therapeutics, Medscape, Mirati Therapeutics, Pfizer, Revolution Medicines, T-Knife, and WebMD; received research funding from AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astellas, AstraZeneca, Bayer, BeiGene USA, Bristol Myers Squibb, Eisai, Eli Lilly, Endeavor, Erasca, Exelixis, F. Hoffmann-La Roche, Genentech, ImmunoGen, Merck, Mirati, NCI-CTEP, Novartis, Pfizer, Revolution Medicines, STCube, TCR2, and VM Oncology; received for travel, accommodations, and expenses from the American Association for Cancer Research, ImmunoGen, Medscape, and Telperian; and has had other ownership interests in Molecular Match, OncoResponse, and Telperian. The other authors (C.B.X., M.K., and Y.P.) do not have a competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}